Royalty Pharma (RPRX) has had the highest return since January 1, 2026 by a US stock in the Pharmaceuticals Industry with a market cap of $10B+, returning 26%.
| ASSET | % RETURN |
|---|---|
Royalty Pharma (RPRX) | 25.97% |
Takeda Pharmaceutical Co Ltd ADR (TAK) | 20.09% |
Johnson & Johnson (JNJ) | 18.66% |
Pfizer (PFE) | 16.21% |
Bristol-Myers Squibb (BMY) | 16.01% |
Novartis AG ADR (NVS) | 15.56% |
Merck (MRK) | 15.36% |
GlaxoSmithKline PLC ADR (GSK) | 14.65% |
Jazz Pharmaceuticals (JAZZ) | 11.07% |
Viatris (VTRS) | 9.97% |
Elanco Animal Health (ELAN) | 1.27% |
Sanofi ADR (SNY) | -1.22% |
Teva Pharma Industries Ltd ADR (TEVA) | -2.98% |
Dr Reddy’s Laboratories Ltd ADR (RDY) | -3.16% |
Zoetis (ZTS) | -6.81% |
Eli Lilly and (LLY) | -11.17% |
Novo Nordisk A-S (NVO) | -26.72% |
